It is possible that treatment recommendations for HER2+ tumours need to take ER-status into account, and that women with ER+/HER2+ tumours have no need for adjuvant therapy in addition to locoregional radiotherapy and endocrine treatment. Here, ERBB2 is linked to neoplasm.